EurekAlert!

Nature Communications: Nivolumab and anlotinib show promising results in advanced stomach cancer

Recent clinical research suggested that Nivolumab and Anlotinib as new combination therapy have shown promising treatment results in advanced stomach and esophageal cancer. The research was conducted ...
Seeking Alpha

Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated ...
The American Journal of Managed Care

Tobacco Use Tied to Immunotherapy Response and Gastric Cancer Mortality

Ever-smokers receiving immunotherapy for gastric and esophageal cancers showed better survival outcomes but higher relapse ...
MedPage Today

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

There was a meaningful reduction in the risk for non-small cell lung cancer (NSCLC) recurrence or death in post-surgical patients treated with perioperative nivolumab (Opdivo) and chemotherapy versus ...
Seeking Alpha

Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for ...

Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo ® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell ...